U.S.–China Biotech & Life Sciences Sector Analysis

Trump–Xi Beijing Summit  |  May 2026

One company, one trade restriction, one diplomatic visit — and the larger story of China's rise in global biomedicine

Prepared by Richstorm.co

Key Takeaways

▸ Illumina attended Beijing not to explore opportunity, but to seek removal from a Chinese regulatory blacklist that cost it 27% of its China revenue.

▸ Big Pharma skipped the summit because $50 billion in U.S.–China deals were already closing through commercial channels — no diplomacy needed.

▸ China's 15th Five-Year Plan names biotechnology as a national breakthrough priority for the first time, extending a self-sufficiency drive that has already made China a net medical device exporter.

▸ The deepest long-term risk for Western life sciences investors is China's genomic data infrastructure build-out, which positions it as a key node in 21st-century precision medicine.

The Illumina Story: A CEO on a Diplomatic Visit

Illumina holds more than 60% of the global market share in DNA sequencing technology — the machines underpinning cancer diagnostics, rare disease research, prenatal testing, and the drug discovery pipelines of virtually every major pharmaceutical company. At its peak, Illumina's China sales reached $500 million annually. By 2024, that figure had fallen to $300 million, driven by the rise of BGI, China's homegrown genomics company, which grew from being one of Illumina's largest customers in 2010 into its most formidable competitor by 2014.

In February 2025, China's Ministry of Commerce placed Illumina on its "Unreliable Entities List" — restricting gene sequencer exports to China and signaling regulatory risk to Chinese customers. The context: Illumina had actively lobbied for the U.S. BIOSECURE Act, legislation aimed at restricting federal funding from flowing to biotechnology firms with ties to Chinese entities of concern, including BGI. China's listing designation followed as a corresponding regulatory response. Illumina's Q1 2026 China revenue fell 27% year over year. Jacob Thaysen's trip to Beijing was a diplomatic effort to address what corporate channels alone had not resolved.

BGI's rise illustrates China's broader approach to technology development: engage with foreign technology, build domestic capability through state financing and procurement preferences, and progressively expand market share. BGI began in 1999 purchasing Illumina machines at scale, acquired U.S. sequencing company Complete Genomics in 2013, and today deploys sequencing infrastructure across more than 100 countries at costs no Western competitor can match.

Big Pharma's Absence: Too Embedded to Need a Summit

The pharmaceutical giants were absent because they didn't need to be there. Pfizer and Eli Lilly CEOs had met Xi Jinping at the China Development Forum just two months earlier. As Trump's delegation boarded Air Force One, Bristol Myers Squibb announced a $15.2 billion partnership with China's Hengrui Pharma covering thirteen drug programs — negotiated entirely through commercial channels.

China's pharmaceutical role has fundamentally shifted. By the first half of 2025, 32% of innovative drug out-licensing globally came from Chinese companies, up from single digits just years prior. Chinese biotechs are producing world-class innovations in antibody-drug conjugates, bispecific antibodies, cell therapies, and GLP-1 receptor agonists. In September 2024, Chinese biotech Akeso's immunotherapy Ivonescimab outperformed Merck's Keytruda in a Phase III trial for non-small cell lung cancer — a result that drew significant attention across the global oncology community.

Big Pharma's absence also reflected a political calculation. The BIOSECURE Act — signed into law in January 2026 — restricts federal contracts from flowing to firms including WuXi AppTec, which helps produce the active ingredient in Lilly's Zepbound and Mounjaro. Being visibly present at a summit hosted by the president who signed that legislation, while navigating compliance obligations around Chinese manufacturing partners, would have been diplomatically untenable.

China's Strategy: The 15th Five-Year Plan

For the first time in any five-year planning document, China's 15th Five-Year Plan names biotechnology as one of eight frontier technologies for breakthrough development — alongside brain science and pharmaceutical innovation. This extends a decade-long self-sufficiency drive that has already transformed medical devices.

Through Made in China 2025, China directed an estimated $47 billion in state support toward medical technology, backed by procurement policies favoring domestic suppliers. The results are measurable: China now manufactures over 90% of its low- and mid-tier medical devices domestically. In 2024, medical device exports reached $48.75 billion, exceeding imports of $35.8 billion for the first time. United Imaging's 7.0T MRI is deployed in over 40 Tier 1 hospitals; Mindray supplies 80% of ASEAN public hospitals with patient monitors.

Pharmaceuticals are next on the same trajectory. China now contributes over 30% of the global innovative drug pipeline. Regulatory reforms since 2015 cut first-in-human clinical trial approval times from 501 days to 87. Chinese companies hold 23 active biosimilar programs for Ozempic alone. Major Western investments — AstraZeneca's $2.5 billion Beijing R&D base, Pfizer's $1 billion "China 2030" plan — are simultaneously developing Chinese scientific capabilities and creating commercial interdependencies that make decoupling costly for both sides.

The most strategically significant dimension is genomics. BGI's National GeneBank is one of the largest repositories of human genetic information in the world, with partnerships spanning more than 100 countries. Illumina's instruments were the global sequencing standard. Their progressive displacement by BGI instruments — first in China, now in Belt and Road partner countries — represents a structural shift in who develops the infrastructure of global precision medicine.

Implications for Investors

The BIOSECURE gap. The Act restricts federal funding flows to Chinese-linked biotech firms but leaves unaddressed the far larger flow of private capital and intellectual property through licensing deals. More than 30% of all major pharma licensing deals now involve a Chinese biotech partner — outside BIOSECURE's scope entirely.

China's constraints are real. Basic scientific discovery — identifying genuinely novel therapeutic targets — still disproportionately originates in Western research environments. China excels at translational speed and cost, not yet at fundamental discovery. Domestic pricing pressure through volume-based procurement also compresses margins for Chinese biotechs, making Western licensing deals a financial necessity as much as a strategic choice.

The summit's outcome. No formal life sciences agreements emerged from Beijing. The $15.2 billion BMS–Hengrui deal illustrated that the commercial relationship is too intertwined to be governed by summits — it will evolve deal by deal, below the level of diplomatic visibility. The harder question — whether U.S.–China life sciences competition produces a bifurcated global ecosystem or remains integrated — will be answered over the coming decade, not in any single meeting.

Conclusion

Illumina's presence in Beijing told one story: a company seeking to recover market access through diplomatic proximity after regulatory and competitive setbacks. Big Pharma's absence told the opposite: companies so deeply embedded in China's biomedical ecosystem that commercial channels serve them better than state visits.

Behind both is China's 15th Five-Year Plan ambition — to move from the world's largest consumer of Western biomedical innovation to one of its primary producers. That transformation is well underway in medical devices, advancing in pharmaceuticals, and taking its most consequential form in genomics infrastructure. How the global life sciences ecosystem navigates that shift will define the sector for the next generation.

RichStorm publishes independent science-driven investment analysis — pharma pipelines, AI infrastructure, supply chain risks, and long-term value creation. Subscribe free to stay ahead. [Subscribe here]

Report prepared based on reporting from GenomeWeb, Fierce Pharma, BioPharma Dive, the Atlantic Council, Ropes & Gray LLP, the U.S.-China Economic and Security Review Commission, CKGSB Knowledge, Carnegie Endowment for International Peace, MedTech Dive, and the U.S. Congress Research Service  |  May 2026